ESMO 2026 | Evaluating the emerging role of EGFR and MET inhibition in head and neck cancer
Paul Swiecicki, MD, University of Michigan, Ann Arbor, MI, comments on the role of EGFR and MET in head and neck cancer, highlighting that MET inhibitors have shown activity alone and in combination with cetuximab, and that amivantamab has the potential to target both pathways, potentially improving response duration. MET has a role in resistance mechanisms to EGFR inhibitors, and targeting both pathways may help avoid downstream escape pathways. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, absolutely. If we look at it, EGFR is a very established target in head and neck cancer through cetuximab. We know through multiple studies over many years, MET has a role in resistance mechanisms, as well as escape to EGFR inhibitors. We’ve known that MET inhibitors have activities alone and in combination with cetuximab and amivantamab, has the potential to hit both those pathways of EGFR and MET to avoid downstream escape pathways and perhaps even improve the duration of response compared to cetuximab...
You know, absolutely. If we look at it, EGFR is a very established target in head and neck cancer through cetuximab. We know through multiple studies over many years, MET has a role in resistance mechanisms, as well as escape to EGFR inhibitors. We’ve known that MET inhibitors have activities alone and in combination with cetuximab and amivantamab, has the potential to hit both those pathways of EGFR and MET to avoid downstream escape pathways and perhaps even improve the duration of response compared to cetuximab.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
